Channel
Concise updates on companies, approvals, partnerships, funding and market moves across MedTech.
The global clinical trial market size is expected to reach $143.46 billion by 2033, with AI and decentralized models reshaping the drug development landscape.
William Blair has recently launched research coverage on multiple biotechnology companies in quick succession and appointed a new head of biopharma investment banking, reflecting the active momentum of capital activity and innovation pipelines in the healthcare and technology sector. This article analyzes the industry trends and market implications behind this development from the perspective of industry media.
The leadership in medical technology innovation is shifting from large enterprises to private and mid-sized companies, with R&D investment, clinical trials, and approval data revealing new industry trends.
Analyze William Blair's recent dynamics as a transaction advisor and in research coverage within the digital health and biotech sectors, interpreting capital flows and industry trends.
This article reviews the important developments in the global medical technology sector during the third week of April 2025, covering financing, FDA approvals, clinical trials, and M&A collaborations, and analyzes the impact of technological trends such as neural interfaces, AI-assisted diagnosis, and leadless pacing on the industry.
Electronic health records giant Epic Systems has recently experienced a wave of senior executive departures, including President Sumit Rana and AI R&D head Seth Hain, among others. This series of personnel changes has sparked industry attention on the company's future strategy and competition in the healthcare technology talent market.
Medtronic completes acquisition of SPR Therapeutics, incorporating Sprint peripheral nerve stimulation devices into its neuromodulation product line, strengthening its position in the rapidly growing non-opioid pain treatment field.
After withdrawing from the most-favored-nation clause, Danish pharmaceutical procurement agency Amgros has filed a multi-million dollar claim against Amgen. Both parties have hired lawyers, and the case may go to court. This incident reflects the deep contradictions in global drug pricing and healthcare policy.
Six biomedical startups from Taiwan, led by Startup Island TAIWAN, held over 100 one-on-one business meetings with global pharmaceutical companies, investors, and research institutions at the BIO 2026 International Convention. Focusing on cutting-edge fields such as AI-assisted diagnostics, antibody therapies, and organoid platforms, this marks the continuous rise of Taiwan's international influence in the medical technology industry.
Advita Ortho presented nine studies at CAOS 2026, showcasing AI-generated shoulder digital twins, automated planning, and surgical navigation for shoulder, knee, and ankle procedures.
According to the latest PwC report, healthcare technology M&A transaction value reached $36.5 billion in the first half of 2026, continuing the ten-year high trend set in 2025, with strategic buyers focusing on high-growth areas and private equity capital actively entering the market.
At the American Diabetes Association Scientific Sessions, Insulet, MiniMed, Dexcom, and Abbott showcased cutting-edge technologies including fully closed-loop insulin delivery systems, new evidence for continuous glucose monitoring, and multi-analyte sensors.
Centered on Fulcrum Therapeutics pausing its sickle cell disease candidate program, Eli Lilly’s RNA exon editing partnership with Ascidian worth up to $1.9 billion, Biohub’s update to its protein biology world model, and new progress in vaccine research, this article analyzes AI Healthcare, Biotech Innovation, and future capital flows from the perspective of the medtech industry.
Siemens Healthineers is partnering with AiM Medical Robotics to integrate MRI scanning with a neurosurgical robotic platform; meanwhile, Procept BioRobotics has completed enrollment in a randomized study on prostate cancer. Together, these two developments point to a trend: medical device companies are accelerating their entry into more high-barrier treatment settings through image guidance, robotic systems, and clinical trials.